journal article·2005-05

Retention of transforming growth factor β1 using functionalized dextran-based hydrogels

Marion Maire, Delphine Logeart-Avramoglou, Marie-Christelle Degat, Frédéric Chaubet

Biomaterials· Volume 26· Issue 14
Publisher page

Abstract

Functionalized dextrans (FD) are anionic water-soluble polymers bearing carboxylate, benzylamide and sulfate groups, which exhibit binding capacity to transforming growth factor-beta1 (TGF-beta1). In this paper, we have investigated the ability of dextran-based hydrogels containing FD, to bind and release recombinant human TGF-beta1. Hydrogels were prepared by chemical crosslink native dextran and FD with sodium trimetaphosphate in 1m NaOH at 50 degrees C. A wide range of hydrogels were prepared as particles ranging of 1-1.6mm of diameter and characterized with various amounts of FD and with different crosslinker feeding ratios (CFR). Dried particles were soaked with recombinant human transforming growth factor-beta1 (rhTGF-beta1) to determine their capacity to deliver the growth factor. Results indicated that the in vitro kinetics releases of rhTGF-beta1 were related to FD and CFR. Retention capacity of rhTGF-beta1 increases with an increase of negative charges of the matrices brought by both phosphate linkages and FD as demonstrated by an additional release of growth factor in high ionic strength solution. Highly crosslinked hydrogels that contained the highest amount of FD (18% (w/w)) retained up to 88% of rhTGF-beta1. Bioactivity of released growth factor was confirmed in a cell assay. These functionalized hydrogels may have important uses for the stabilization and the protection of rhTGF-beta1 as entrapment systems and could be applied to other proteins of clinical interest.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Hydrogels: synthesis, properties, applications · Proteoglycans and glycosaminoglycans research · Electrospun Nanofibers in Biomedical Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (37)

Show source-provided references
1. Materials for protein delivery in tissue engineering10.1016/S0169-409X(98)00021-0 ↗
2. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor10.1007/BF00437470 ↗
3. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate10.1002/1097-4636(200108)56:2<216::AID-JBM1086>3.0.CO;2-N ↗
4. Collagen and heparin matrices for growth factor delivery10.1016/S0168-3659(97)00055-2 ↗
5. Binding and release of basic fibroblast growth factor from heparinized collagen matrices10.1016/S0142-9612(00)00418-X ↗
6. Heparin-carrying polystyrene (HCPS)-bound collagen substratum to immobilize heparin-binding growth factors and to enhance cellular growth10.1002/1097-4636(20010915)56:4<536::AID-JBM1125>3.0.CO;2-# ↗
7. Development of fibrin derivatives for controlled release of heparin-binding growth factors10.1016/S0168-3659(99)00221-7 ↗
8. Action of microparticles of heparin and alginate crosslinked gel when used as injectable artificial matrices to stabilize basic fibroblast growth factor and induce angiogenesis by controlling its release10.1002/jbm.a.10061 ↗
9. Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties10.1002/(SICI)1097-4636(1999)48:4<578::AID-JBM26>3.0.CO;2-8 ↗
10. New investigations on heparin-like derivatized dextrans10.1016/S0144-8617(96)00171-3 ↗
11. Anticoagulant properties of dextranmethylcarboxylate benzylamide sulfate (DMCBSu); a new generation of bioactive functionalized dextran10.1016/S0008-6215(01)00066-0 ↗
12. Interaction of specifically chemically modified dextrans with transforming growth factor beta110.1016/S0006-2952(01)00834-6 ↗
13. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF10.1002/jcp.1041500126 ↗
14. Inhibition of human breast epithelial HBL100 cell proliferation by a dextran derivative (CMDB7)10.1006/bbrc.1997.7483 ↗
15. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165).KDR Complexes10.1074/jbc.M101117200 ↗
16. Inhibition of MCF-7ras tumor growth by carboxymethyl benzylamide dextran
17. Anticoagulant activity of dextran derivatives10.1002/(SICI)1097-4636(199807)41:1<49::AID-JBM6>3.0.CO;2-Q ↗
18. Heparin and non-heparin-like dextrans differentially modulate endothelial cell proliferation10.1002/jbm.10072 ↗
19. Hydrogels for biomedical applications10.1016/S0169-409X(01)00239-3 ↗
20. Preparation, characterisation, and rheological behaviour of strach-sodium trimetaphosphate hydrogels10.1002/star.19900420404 ↗
21. Smith PS. In: Lineback DR, Inglett GE, Lineback DR, Inglett GEs. Food carbohydrates. Westport: Avi Press; 1982. p. 237–62.
22. Hamilton RM, Paschall EF. In: Whistler RL, Paschall EF, Whistler RL, Paschall EFs. Starch: chemistry and technology. New York: Academic Press; 1965. p. 351–66.
23. Cross-linking of wheat starch and hydroxypropylated wheat starch in alkaline slurry with sodium trimetaphosphate10.1016/S0144-8617(97)00037-4 ↗
24. Associative pullulan gels and their interaction with biological active substances10.1016/S0168-3659(02)00169-4 ↗
25. Phosphated crosslinked guar for colon-specific drug delivery10.1016/S0168-3659(99)00179-0 ↗
26. Dextrans for targeted and sustained delivery of therapeutic and imaging agents10.1016/S0168-3659(00)00302-3 ↗
27. The dextrans–clinical data
28. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct10.1006/abio.1994.1042 ↗
29. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans10.1073/pnas.88.7.2768 ↗
30. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets10.1073/pnas.76.9.4350 ↗
31. Comparison of transforming growth factor beta and a human tumour-derived suppressor factor10.1007/BF01744940 ↗
32. Partial purification of an immunosuppressive protein from a human tumor cell line and analysis of its relationship to transforming growth factor beta10.1016/0008-8749(89)90094-4 ↗
33. Cross-linked amylose as matrix for drug controlled release. X-ray and FT-IR structural analysis10.1016/S0144-8617(98)00058-7 ↗
34. Bone regeneration by transforming growth factor-β1 released from a biodegradable hydrogel10.1016/S0168-3659(99)00129-7 ↗
35. Biodegradable amphiphilic multiblock copolymers and their implications for biomedical applications10.1016/S0168-3659(99)00126-1 ↗
36. In vitro release of transforming growth factor-[beta]1 from gelatin microparticles encapsulated in biodegradable, injectable oligo(poly(ethylene glycol) fumarate) hydrogels10.1016/S0168-3659(03)00258-X ↗
37. Polymeric system for dual growth factor delivery10.1038/nbt1101-1029 ↗